NCT07209332Phase 2Enrolling by invitation

Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy

Study sponsor: Wave Life Sciences USA, Inc.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2029-03Estimated

Enrollment · participants175Estimated

Source updated2026-03-06Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-06 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Enrolling by invitation

Check registry source

Study details

Conditions studied

Duchenne Muscular Dystrophy

Treatments or interventions studied

WVE-N531Drug

Primary outcomes · main study measures

Read the study measures

measure: Number of participants with treatment related adverse events as assessed by the following parameters:; description: * Complete Physical examination, including height and weight * Vital Signs (via blood pressure, temperature and pulse) * Safety Laboratory Tests (including complete blood cell count, urinalysis and clinical chemistry) * ECG (12- Lead single tracing) * ECHO (including left ventricular ejection fraction) * Pulmonary Function Tests (including Peak Flow Rate, Cough Peak Flow, Forced Vital Capacity and Maximum Inspiratory Pressure); timeFrame: Time Frame: Week 0 through Week 96

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history